HONG KONG – An artificial compound derived from vitamin A, acyclic retinoid (ACR), has been shown to selectively target cancer stem cells (CSCs) and reduce the post-therapeutic recurrence of hepatocellular carcinoma (HCC) in a new study and is currently in phase III trials for that indication in Asia.